Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study

Blood. 2020 Jul 2;136(1):144-147. doi: 10.1182/blood.2020006941.

Authors

Douglas Tremblay¹, Maaike van Gerwen^{2

3}, Mathilda Alsen², Santiago Thibaud¹, Alaina Kessler¹, Sangeetha Venugopal¹, Iman Makki¹, Qian Qin¹, Sirish Dharmapuri¹, Tomi Jun¹, Sheena Bhalla¹, Shana Berwick¹, Jonathan Feld¹, John Mascarenhas¹, Kevin Troy¹, Caroline Cromwell¹, Andrew Dunn⁴, William K Oh¹, Leonard Naymagon¹

Affiliations

¹ Division of Hematology and Medical Oncology, Tisch Cancer Institute.
² Department of Otolaryngology-Head and Neck Surgery.
³ Institute for Translational Epidemiology, and.
⁴ Division of Hospital Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Anticoagulants / therapeutic use*
Betacoronavirus / drug effects
COVID-19
Coronavirus Infections / drug therapy
Coronavirus Infections / epidemiology*
Female
Humans
Male
Middle Aged
Pandemics
Platelet Aggregation Inhibitors / therapeutic use*
Pneumonia, Viral / drug therapy
Pneumonia, Viral / epidemiology*
Propensity Score
Protective Agents / therapeutic use*
Protective Factors
Retrospective Studies
SARS-CoV-2
Survival Analysis

Substances

Anticoagulants
Platelet Aggregation Inhibitors
Protective Agents